Thus, cancer cells with high level of RAS mutation are highly vulnerable to glycolytic inhibitors, as evidenced by the downregulation of glycolytic enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and impaired tumor growth in vitamin C treated KRAS mutant mouse intestinal cancers [52]. The gene discussed is KRAS; the disease is cancer.